-

2020 Drug Patent Database Subscription: U.S. Drug Prices - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Drug Patent Database Subscription: US Drug Prices" newsletter has been added to ResearchAndMarkets.com's offering.

This subscription was created to answer a simple question: When do drug patents expire? Your needs evolve as the industry keeps changing. Since then dozens of additional datasets have been added by aggressive adaptation based on your needs.

This subscription for the US Drug Prices portion of the database offers information on:

  • Brand vs. Generic Drug Price Gap, find generic entry opportunities
  • Average Pharmacy Cost, set reasonable launch prices
  • Best-Available Price, see price ranges

Global biopharmaceutical markets face constant change. To remain competitive you need to anticipate what's next. The analyst understands and works together with you to help you make better decisions. If you are expanding into new markets, looking inward for growth opportunities, or seeking to improve your current activities and need to find information quickly, this subscription can help.

The analyst provides relevant context and ensures you have the information you need at your fingertips. This helps you see opportunities and enrich your analysis, without overwhelming you with options or asking you to perform many searches. The sophisticated algorithms are also tailored to help you extract valuable insights.

With a single click, you can find answers to complex questions such as:

  • Which drugs have no patents and no competitors?
  • What are all the patents covering any given dosage form (e.g. injectables)?
  • What is the earliest generic entry opportunity date for a drug with dozens of patents?

The analyst focuses on delivering the greatest value and lowest cost by directing attention to high-impact problems, giving you the relevant information you need.

Key Topics Covered

  1. Brand vs. Generic Drug Price
  2. Average Pharmacy Cost
  3. Best-Available Price

Companies Mentioned

  • 3M Pharmaceuticals
  • Abbott Laboratories
  • AbbVie
  • Acadia Pharmaceuticals
  • Acorda Therapeutics
  • Actavis
  • Actelion
  • Adcock Ingram
  • Advanced Chemical Industries
  • Advaxis
  • ACG Worldwide
  • Ajanta Pharma
  • Alcon
  • Alembic Pharmaceuticals Ltd
  • Alexion Pharmaceuticals
  • Alkaloid AD Skopje
  • Alkermes
  • Allergan
  • Alliance Boots
  • Almirall
  • Alphapharm
  • Altana Pharma AG
  • Amgen
  • Anfatis
  • Apotex Inc.
  • Aspen Pharmacare
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo Pharma
  • Avax Technologies
  • Avella Specialty Pharmacy
  • Axcan Pharma
  • Bargn Farmaceutici Phils Co
  • Barr Pharmaceuticals
  • Bausch & Lomb
  • Baxalta
  • Baxter International
  • Bayer Schering Pharma AG
  • Beximco Pharmaceuticals Ltd
  • Bial
  • Biocon
  • Biogen
  • Biolex
  • BioMarin Pharmaceutical
  • Bionovo
  • Biotecnol
  • Biovail
  • Biovitrum
  • Bluepharma
  • Boehringer-Ingelheim
  • Bosnalijek
  • Bristol-Myers Squibb
  • BTG plc
  • Cadila Healthcare
  • Canadian Plasma Resources
  • Catalent
  • The Cathay Drug Co., Inc.
  • Celgene
  • Cephalon
  • Chiesi Farmaceutici S.p.A.
  • Chugai Pharmaceutical Co.
  • CinnaGen
  • Cipla
  • Clovis Oncology
  • CoCo Therapeutics
  • Concordia Healthcare
  • Covance
  • Crucell
  • CSL Limited
  • Dabur
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Dawakhana Shifaul Amraz
  • Debiopharm
  • Deurali-Janta Pharmaceuticals
  • Diabetology Ltd
  • Diffusion Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Ego Pharmaceuticals
  • Eisai
  • Elder Pharmaceuticals
  • Eli Lilly and Company
  • Emcure Pharmaceuticals
  • Emergent BioSolutions
  • Endo Pharmaceuticals
  • Eskayef Bangladesh Limited
  • Esteve
  • F. Hoffmann-La Roche Ltd., which owns Genentech and Chugai Pharmaceuticals
  • Fabre-Kramer Pharmaceuticals
  • Ferring Pharmaceuticals
  • Fresenius Kabi
  • Fresenius Medical Care
  • Galderma Laboratories
  • Gedeon Richter Ltd.
  • General Pharma
  • Gilead Sciences
  • Glatt group
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • GPC Biotech
  • Grifols
  • Grindeks
  • Gulf Pharmaceutical Industries (Julphar)
  • G.F. Harvey Company
  • Huadong Medicine
  • Help Remedies
  • Hetero Drugs
  • Hexal Australia
  • Hikma Pharmaceuticals
  • Hoffmann-La Roche
  • Horizon Pharma
  • Hovione
  • Incepta Pharmaceuticals
  • Institute for OneWorld Health
  • Intas Biopharmaceuticals
  • Interphil Laboratories
  • Ionis Pharmaceuticals
  • Ipca Laboratories
  • Ipsen
  • Janssen Pharmaceutica
  • Jenapharm
  • JN-International Medical Corporation
  • Johnson & Johnson
  • Julphar
  • Juno Therapeutics
  • Kimia Farma
  • Kyowa Hakko Kirin
  • Lundbeck
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • MannKind Corporation
  • McGuff
  • Medinfar
  • Melior Discovery
  • Menarini
  • Merck & Co.
  • Merck KGaA
  • Mitsubishi Pharma
  • Mylan
  • Mayne Pharma
  • NovaBay Pharmaceuticals
  • Novartis
  • Novo Nordisk
  • Noxxon
  • Octapharma
  • Orexo
  • OrgaNext
  • Orion Pharma
  • Ortho-McNeil Pharmaceutical
  • Otsuka Pharmaceutical Co.
  • Panacea Biotec
  • Par Pharmaceutical
  • Patheon
  • Perrigo
  • Pfizer
  • Pharmaceutical Product Development
  • Pharma Medica
  • Pharma Nord
  • Pharmacosmos
  • Pharmascience
  • Pierre Fabre Group
  • Piramal Healthcare
  • Pliva
  • Procter & Gamble
  • Purdue Pharma
  • Ranbaxy Laboratories
  • Reckitt Benckiser
  • Regeneron Pharmaceuticals
  • Renovo PLC
  • Repligen
  • Rubicon Research
  • Salix Pharmaceuticals
  • Sanofi
  • Serum Institute of India
  • Servier Laboratories
  • Shionogi
  • Shire plc
  • SIGA Technologies
  • Sigma Pharmaceuticals
  • Sinopharm Group
  • Solvay Group
  • Square Pharmaceuticals
  • STADA Arzneimittel
  • Strides Arcolab
  • Sun Pharmaceutical
  • Sunovion
  • Takeda Pharmaceutical Co.
  • Tasly
  • Teva Pharmaceuticals
  • Taro Pharmaceuticals
  • Torrent Pharmaceuticals
  • Turing Pharmaceuticals
  • UCB
  • Unichem Laboratories
  • USV Private Limited
  • Valeant Pharmaceuticals International
  • Veloxis Pharmaceuticals
  • Vertex Pharmaceuticals
  • Vion Pharmaceuticals, Inc.
  • Wallace Pharmaceuticals
  • Wockhardt
  • Yuhan Corporation
  • Zandu Pharmaceuticals
  • Zentiva

For more information about this newsletter visit https://www.researchandmarkets.com/r/qk5o7o

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

1 Day Clinical Trial Agreements Training Course: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets (Mar 18, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets Training Course (Mar 18, 2026)" training has been added to ResearchAndMarkets.com's offering. The life sciences sector is heavily regulated and CTAs are some of the most important agreements for companies operating in this sector. Having appropriate CTAs in place is therefore essential for managing relationships between the diffe...

Navigating EU (European Union) and FDA (Food and Drug Administration) Regulations for Drug/Device and Device/Drug Combination Products Training Course (Mar 2nd - Mar 3rd, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Navigating EU (European Union) and FDA (Food and Drug Administration) Regulations for Drug/Device and Device/Drug Combination Products Training Course (Mar 2nd - Mar 3rd, 2026)" training has been added to ResearchAndMarkets.com's offering. Understand the regulatory frameworks governing drug/device and device/drug combinations in the European Union and the USA. The demarcation between medicinal products and devices is becoming ever more important and, with the conve...

Wedding Rings Market Trends, Shares and Growth Prospects 2025-2030 - Cultural and Social Trends Around Minimalism and Modern Design Drive Adoption of Non-Traditional Styles - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Wedding Rings - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Wedding Rings was valued at US$56.7 Billion in 2024 and is projected to reach US$80.7 Billion by 2030, growing at a CAGR of 6.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The wedding ring market is expanding due to a combin...
Back to Newsroom